<DOC>
	<DOC>NCT00268749</DOC>
	<brief_summary>This is an open label trial of the NMDA agonist glycine used alone for symptoms that appear to be prodromal for schizophrenia in adolescents and young adults.</brief_summary>
	<brief_title>Glycine Treatment of Prodromal Symptoms</brief_title>
	<detailed_description />
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Prodromal Symptoms</mesh_term>
	<mesh_term>Glycine</mesh_term>
	<criteria>age 1435 meets SIPS criteria for psychosis prodrome current antipsychotic medication more than 4 weeks of antipsychotic medication lifetime</criteria>
	<gender>All</gender>
	<minimum_age>14 Years</minimum_age>
	<maximum_age>35 Years</maximum_age>
	<verification_date>March 2012</verification_date>
</DOC>